The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | PALOMA-3 results: subcutaneous amivantamab + lazertinib in NSCLC could replace IV formulation
Natasha Leighl, MD, FASCO, Princess Margaret Cancer Centre, Toronto, Canada, discusses the Phase III PALOMA-3 (NCT05388669) results, which she hopes will lead to the registration and approval of the subcutaneous formulation of amivantamab in combination with lazertinib in non-small cell lung cancer (NSCLC). This advancement could replace all current intravenous (IV) indications of amivantamab for patients. The benefits include reduced hospital time, less disruption to patients’ lives, fewer infusion-related reactions, and a lower incidence of blood clots. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Beigene; BMS; Janssen; MSD Oncology; Takeda
Research Funding – AstraZeneca Canada (Inst); Inivata/NeoGenomics (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses – AstraZeneca
